MA-OUTSEER
14.9.2021 15:02:07 CEST | Business Wire | Press release
Outseer, the leader in payment authentication and monitoring solutions, has published its third quarter Fraud & Payments Report, confirming that a massive $100 billion in transactions in 2021 alone have been protected by Outseer’s 3-D secure payments authentication technology. The report also reveals continued explosive growth of worldwide 3-D Secure transactions due to skyrocketing adoption of online shopping and new PSD2 mandates. The Q3 report installment features insights from April through June of 2021 as captured through the Outseer Global Data Network, and collected while authenticating consumer transactions and investigating threats on behalf of Outseer customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005639/en/
According to the report, 3-D Secure transactions, a global standard supported by EMVCo to authenticate digital payment transactions, have grown by an impressive 79% over the past 18 months, with Q2 year-over-year growth of 44%.
For the latest standard using EMV®3-D Secure 2.x technology specifically, the report shows a continued, steady increase across all geographies. Europe recorded the most significant jump, where 2.x transactions comprised a 46% share of all 3-D Secure transactions examined in Q2, 2021, growing nearly seven times from the 7% share reported in Q3 2020. The Americas witnessed nearly four times growth, with 2.x transaction volume jumping from a 10% share in Q3, 2020 to a 37% share in Q2, 2021.
This global share increase in 2.x transactions can be attributed to a pandemic-fueled spike in card-not-present (CNP) transactions in addition to looming Payment Services Directive (PSD2) enforcement dates. Moreover, the 2.x authentication standard from EMVCo supports consumer-friendly experiences in native mobile app environments tailed to the merchant. As the 3-D Secure standard directly supports PSD2 and Strong Customer Authentication (SCA) regulations, adoption of the 2.x version to authenticate payment transactions will increase beyond March of 2022 when PSD2 regulations go into effect across all of Europe.
“As the pandemic fuels an unprecedented spike in digital shopping globally, we’re excited to see card issuers and merchants embrace the gold standard of payment authentication technology,” said Armen Najarian, CMO and Chief Identity Officer at Outseer. “The latest 3-D Secure standard delivers the shopping experiences consumer demand, with the positive economics and growth that card issuers and merchants require. We expect the global payments ecosystem to deepen its use of 3-D Secure to authenticate digital transactions.”
Other notable insights from the Q3 Outseer Fraud & Payments Report include:
- Over 49,000 attacks detected by the Outseer Anti-Fraud Command Center in Q2 2021 alone
- Brand Abuse attacks continue to be the most dominant attack vector for the third consecutive quarter, comprising 49% of all attack types
- 70% of fraudulent transactions in digital banking originated through the mobile channel, with the biggest rise seen in mobile app fraud
- The presence of Rogue Mobile Apps increased 66% from last quarter and 140% year-over-year. Fraudsters are creating fake banking apps and uploading them to various app stores to infect consumers’ devices with malware and harvest user credentials for account takeover activities
- Outseer recovered over 4.5 million unique compromised cards and card previews from online card stores and fraud communication channels in Q2 2021
Download the Q3, 2021 Outseer Fraud & Payments Report here: https://www.outseer.com/fraud-report-q3-2021/
About Outseer
Outseer, an RSA Company, empowers the digital economy to grow by authenticating billions of transactions annually. Our payment and account monitoring solutions increase revenue and reduce customer friction for card issuing banks, payment processors, and merchants worldwide. Leveraging 20 billion annual transactions from 6,000 global institutions contributing to the Outseer Data Network, our identity-based science delivers the highest fraud detection rates and lowest customer intervention in the industry. See what others can’t at outseer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005639/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
